title: Clinical trials: More trials, fewer tribulations.
authors.forename: Michael
authors.initials: M
authors.lastname: Eisenstein
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols; D014408:Biomarkers, Tumor / Q000235:genetics; D001943:Breast Neoplasms / Q000145:classification / Q000188:drug therapy / Q000235:genetics; D002986:Clinical Trials as Topic / Q000379:methods* / Q000639:trends*; D000077547:Crizotinib; D004252:DNA Mutational Analysis; D017277:Drug Approval; D019008:Drug Resistance, Neoplasm; D005260:Female; D000077156:Gefitinib; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D009369:Neoplasms / Q000145:classification / Q000188:drug therapy* / Q000235:genetics*; D018579:Patient Selection; D048493:Proto-Oncogene Proteins B-raf / Q000235:genetics; D011720:Pyrazoles / Q000627:therapeutic use; D011725:Pyridines / Q000627:therapeutic use; D011799:Quinazolines / Q000627:therapeutic use; D011804:Quinolines / Q000627:therapeutic use; D018401:Sample Size
chemical_list: D014408:Biomarkers, Tumor; D011720:Pyrazoles; D011725:Pyridines; D011799:Quinazolines; D011804:Quinolines; D000077547:Crizotinib; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf; C487932:neratinib; D000077156:Gefitinib